Given the diversity of p53 variants in human cancers, a systematic evaluation of common tumor-associated p53 mutants across distinct virus families will be necessary to determine whether antiviral effects are generalizable or restricted to particular mutations, cell types, and infection stages. The gene discussed is TP53; the disease is neoplasm.